Their findings suggest that triclabendazole induces GSDME-dependent pyroptosis through caspase-3 activation, at least partly by enhancing the ROS/JNK/Bax-mitochondrial apoptotic pathway, thereby offering valuable insights into the potential new application of this existing drug in breast cancer treatment. This evidence concerns the gene CASP3 and breast carcinoma.